Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival

C. Ling, Celso Pouget, F. Rech, Robin Pflaum, M. Treffel, F. Bielle, K. Mokhtari, Jean-Matthieu Casse, J. Vignaud, M. Kalamarides, M. Peyre, G. Gauchotte
{"title":"Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival","authors":"C. Ling, Celso Pouget, F. Rech, Robin Pflaum, M. Treffel, F. Bielle, K. Mokhtari, Jean-Matthieu Casse, J. Vignaud, M. Kalamarides, M. Peyre, G. Gauchotte","doi":"10.1093/jnen/nlw095","DOIUrl":null,"url":null,"abstract":"Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p = 0.0004, and p = 0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p = 0.017, p = 0.021, and p = 0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p = 0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.","PeriodicalId":16434,"journal":{"name":"Journal of Neuropathology & Experimental Neurology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuropathology & Experimental Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jnen/nlw095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p = 0.0004, and p = 0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p = 0.017, p = 0.021, and p = 0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p = 0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脑膜瘤的内皮细胞肥大和微血管增生与较高的组织学分级和较短的无进展生存期相关
微血管增生(MVP)是胶质母细胞瘤的标志。内皮细胞肥大(ECH),也称为内皮增生,与胶质瘤患者较短的生存期相关。然而,这两种形态学特征在脑膜瘤中的预后价值尚未得到研究。本研究的目的是评估脑膜瘤中血管生成的预后价值,尤其是ECH、MVP和微血管密度,在139例脑膜瘤中使用针对CD34和CD105(新生血管标志物)的抗体进行免疫组织化学评估。ECH、MVP和CD105免疫反应性与较高的组织学分级显著相关(p < 0.0001, p = 0.0004, p = 0.0003)。ECH和MVP免疫反应与较短的无进展生存时间(PFS)显著相关(p = 0.017, p = 0.021, p = 0.137),而CD105免疫反应与PFS无关(p = 0.021, p = 0.137)。在Cox多变量分析中,ECH是较短PFS的独立预测因子(p = 0.028)。因此,ECH和MVP是脑膜瘤PFS较短的标志,并与分级显著相关。这些发现为抗血管生成疗法的使用提供了见解。需要进一步的研究来确定这些标记物是否可以让我们识别可以从抗血管生成治疗中获益的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Stirling Carpenter, MD February 27, 1929–February 19, 2021 William G. Ellis, MD June 12, 1932–January 16, 2021 Autobiography Series: A Life of Anecdotes Meritorious Contributions to Neuropathology In Memoriam: Carol Petito, MD
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1